The blood-brain barrier in health and disease

Annals of Neurology

Volumn 72, Issue 5, 2012, Pages 648-672

  Daneman, Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; COLLAGEN TYPE 4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENTACTIN; GLUCOSE TRANSPORTER 1; GLYCOPROTEIN; JUNCTIONAL ADHESION MOLECULE; LAMININ; LEUKOCYTE ADHESION MOLECULE; NERVE CELL ADHESION MOLECULE; OCCLUDIN; PADGEM PROTEIN; TETRASPANIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; ARTICLE; ASTROCYTE; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; CELL ADHESION; CELLULAR DISTRIBUTION; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; ENDOTHELIUM CELL; EPILEPSY; EXTRACELLULAR MATRIX; GLYCOCALYX; HUMAN; IMMUNOCOMPETENT CELL; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MULTIPLE SCLEROSIS; NEUROVASCULAR UNIT; PARKINSON DISEASE; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; SEQUENCE HOMOLOGY; SMOOTH MUSCLE FIBER; T LYMPHOCYTE ACTIVATION; TIGHT JUNCTION; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE CELL;

BLOOD-BRAIN BARRIER; GENE EXPRESSION REGULATION; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 84870408539     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23648     Document Type: Article

References (341)

1. Aird WC,. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007; 100: 174-190. (Pubitemid 46208718)
2. Aird WC,. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100: 158-173. (Pubitemid 46208717)
3. Gloor SM, Wachtel M, Bolliger MF, et al. Molecular and cellular permeability control at the blood-brain barrier. Brain Res Brain Res Rev 2001; 36: 258-264. (Pubitemid 33020756)
4. Rubin LL, Staddon JM,. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999; 22: 11-28. (Pubitemid 29144879)
5. Saunders NR, Ek CJ, Habgood MD, Dziegielewska KM,. Barriers in the brain: A renaissance? Trends Neurosci 2008; 31: 279-286.
6. Zlokovic BV,. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
7. Alvarez JI, Cayrol R, Prat A,. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 2011; 1812: 252-264.
8. Sandoval KE, Witt KA,. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008; 32: 200-219.
9. Bowman GL, Kaye JA, Moore M, et al. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 2007; 68: 1809-1814. (Pubitemid 46791393)
10. Jeynes B, Provias J,. The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease. J Neurosci Res 2011; 89: 22-28.
11. Zipser BD, Johanson CE, Gonzalez L, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007; 28: 977-986. (Pubitemid 46635913)
12. Chung YC, Ko HW, Bok E, et al. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010; 43: 225-232.
13. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC,. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999; 353: 981-982. (Pubitemid 29132612)
14. Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005; 57: 176-179. (Pubitemid 40179854)
15. Donnenfeld H, Kascsak RJ, Bartfeld H,. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol 1984; 6: 51-57. (Pubitemid 14132684)
16. Engelhardt JI, Appel SH,. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 1990; 47: 1210-1216. (Pubitemid 20381002)
17. Leonardi A, Abbruzzese G, Arata L, et al. Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol 1984; 231: 75-78. (Pubitemid 14137306)
18. Armulik A, Abramsson A, Betsholtz C,. Endothelial/pericyte interactions. Circ Res 2005; 97: 512-523. (Pubitemid 41361741)
19. Tilling T, Engelbertz C, Decker S, et al. Expression and adhesive properties of basement membrane proteins in cerebral capillary endothelial cell cultures. Cell Tissue Res 2002; 310: 19-29.
20. Carmignoto G, Gomez-Gonzalo M,. The contribution of astrocyte signalling to neurovascular coupling. Brain Res Rev 2010; 63: 138-148.
21. Zhang Y, Barres BA,. Astrocyte heterogeneity: An underappreciated topic in neurobiology. Curr Opin Neurobiol 2010; 20: 588-594.
22. Williams K, Alvarez X, Lackner AA,. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 2001; 36: 156-164. (Pubitemid 33055904)
23. Brightman MW, Reese TS,. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969; 40: 648-677.
24. Reese TS, Karnovsky MJ,. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967; 34: 207-217.
25. Westergaard E, Brightman MW,. Transport of proteins across normal cerebral arterioles. J Comp Neurol 1973; 152: 17-44.
26. Loscher W, Potschka H,. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005; 76: 22-76. (Pubitemid 41033402)
27. Simpson IA, Carruthers A, Vannucci SJ,. Supply and demand in cerebral energy metabolism: The role of nutrient transporters. J Cereb Blood Flow Metab 2007; 27: 1766-1791. (Pubitemid 47624552)
28. Spector R,. Nutrient transport systems in brain: 40 years of progress. J Neurochem 2009; 111: 315-320.
29. Ueno M, Nakagawa T, Wu B, et al. Transporters in the brain endothelial barrier. Curr Med Chem 2010; 17: 1125-1138.
30. Van Teeffelen JW, Brands J, Stroes ES, Vink H,. Endothelial glycocalyx: sweet shield of blood vessels. Trends Cardiovasc Med 2007; 17: 101-105. (Pubitemid 46533936)
31. Vink H, Duling BR,. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 1996; 79: 581-589. (Pubitemid 26276918)
32. Stewart PA, Wiley MJ,. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: A study using quail-chick transplantation chimeras. Dev Biol 1981; 84: 183-192. (Pubitemid 11092411)
33. Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature 2010; 468: 557-561.
34. Daneman R, Zhou L, Kebede AA, Barres BA,. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010; 468: 562-566.
35. Janzer RC, Raff MC,. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987; 325: 253-257. (Pubitemid 17049884)
36. Li F, Lan Y, Wang Y, et al. Endothelial Smad4 maintains cerebrovascular integrity by activating N-cadherin through cooperation with Notch. Dev Cell 2011; 20: 291-302.
37. Tang DG, Conti CJ,. Endothelial cell development, vasculogenesis, angiogenesis, and tumor neovascularization: An update. Semin Thromb Hemost 2004; 30: 109-117. (Pubitemid 38457305)
38. Armulik A, Genove G, Betsholtz C,. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21: 193-215.
39. Winkler EA, Bell RD, Zlokovic BV,. Central nervous system pericytes in health and disease. Nat Neurosci 2011; 14: 1398-1405.
40. Goritz C, Dias DO, Tomilin N, et al. A pericyte origin of spinal cord scar tissue. Science 2011; 333: 238-242.
41. Del Zoppo GJ, Milner R, Mabuchi T, et al. Vascular matrix adhesion and the blood-brain barrier. Biochem Soc Trans 2006; 34: 1261-1266. (Pubitemid 46769034)
42. Sorokin L,. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010; 10: 712-723.
43. Agrawal S, Anderson P, Durbeej M, et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 2006; 203: 1007-1019.
44. Wu C, Ivars F, Anderson P, et al. Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med 2009; 15: 519-527.
45. Attwell D, Buchan AM, Charpak S, et al. Glial and neuronal control of brain blood flow. Nature 2010; 468: 232-243.
46. Petzold GC, Murthy VN,. Role of astrocytes in neurovascular coupling. Neuron 2011; 71: 782-797.
47. Alvarez JI, Dodelet-Devillers A, Kebir H, et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 2011; 334: 1727-1731.
48. Raub TJ,. Signal transduction and glial cell modulation of cultured brain microvessel endothelial cell tight junctions. Am J Physiol 1996; 271: C495-C503.
49. Rist RJ, Romero IA, Chan MW, et al. F-actin cytoskeleton and sucrose permeability of immortalised rat brain microvascular endothelial cell monolayers: effects of cyclic AMP and astrocytic factors. Brain Res 1997; 768: 10-18. (Pubitemid 27433471)
50. Rubin LL, Hall DE, Porter S, et al. A cell culture model of the blood-brain barrier. J Cell Biol 1991; 115: 1725-1735. (Pubitemid 21910012)
51. Wosik K, Cayrol R, Dodelet-Devillers A, et al. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 2007; 27: 9032-9042. (Pubitemid 47312066)
52. Haj-Yasein NN, Vindedal GF, Eilert-Olsen M, et al. Glial-conditional deletion of aquaporin-4 (Aqp4) reduces blood-brain water uptake and confers barrier function on perivascular astrocyte endfeet. Proc Natl Acad Sci U S A 2011; 108: 17815-17820.
53. Hickey WF, Kimura H,. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988; 239: 290-292. (Pubitemid 18061496)
54. Polfliet MM, Zwijnenburg PJ, van Furth AM, et al. Meningeal and perivascular macrophages of the central nervous system play a protective role during bacterial meningitis. J Immunol 2001; 167: 4644-4650. (Pubitemid 32954345)
55. Unger ER, Sung JH, Manivel JC, et al. Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: A Y-chromosome specific in situ hybridization study. J Neuropathol Exp Neurol 1993; 52: 460-470. (Pubitemid 23269194)
56. Vass K, Hickey WF, Schmidt RE, Lassmann H,. Bone marrow-derived elements in the peripheral nervous system. An immunohistochemical and ultrastructural investigation in chimeric rats. Lab Invest 1993; 69: 275-282. (Pubitemid 23315711)
57. Ibrahim MZ, Koshayan DS, Khreis YM,. The mast cells of the mammalian central nervous system. VI. Uptake of tritiated thymidine by mast cells, neurolipomastocytoid cells and other elements of the central nervous system. Acta Anat (Basel) 1980; 108: 102-114. (Pubitemid 10073469)
58. Wilhelm M, Silver R, Silverman AJ,. Central nervous system neurons acquire mast cell products via transgranulation. Eur J Neurosci 2005; 22: 2238-2248. (Pubitemid 41653537)
59. Ajami B, Bennett JL, Krieger C, et al. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 2007; 10: 1538-1543. (Pubitemid 350175883)
60. Streit WJ, Conde JR, Fendrick SE, et al. Role of microglia in the central nervous system's immune response. Neurol Res 2005; 27: 685-691. (Pubitemid 41513077)
61. Persidsky Y, Ghorpade A, Rasmussen J, et al. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol 1999; 155: 1599-1611.
62. Hudson LC, Bragg DC, Tompkins MB, Meeker RB,. Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells. Brain Res 2005; 1058: 148-160. (Pubitemid 41416809)
63. Farquhar MG, Palade GE,. Junctional complexes in various epithelia. J Cell Biol 1963; 17: 375-412.
64. Powell DW,. Barrier function of epithelia. Am J Physiol 1981; 241: G275-G288.
65. Furuse M,. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol 2010; 2: A002907.
66. Gupta IR, Ryan AK,. Claudins: unlocking the code to tight junction function during embryogenesis and in disease. Clin Genet 2010; 77: 314-325.
67. Anderson JM, Van Itallie CM,. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol 2009; 1: A002584.
68. Knipp GT, Ho NF, Barsuhn CL, Borchardt RT,. Paracellular diffusion in Caco-2 cell monolayers: effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J Pharm Sci 1997; 86: 1105-1110. (Pubitemid 27430913)
69. Van Itallie CM, Holmes J, Bridges A, et al. The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell Sci 2008; 121: 298-305. (Pubitemid 351356701)
70. Watson CJ, Rowland M, Warhurst G,. Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers. Am J Physiol Cell Physiol 2001; 281: C388-C397.
71. Furuse M, Fujita K, Hiiragi T, et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998; 141: 1539-1550. (Pubitemid 28309169)
72. Furuse M, Sasaki H, Fujimoto K, Tsukita S,. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J Cell Biol 1998; 143: 391-401. (Pubitemid 28487858)
73. Kubota K, Furuse M, Sasaki H, et al. Ca(2+)-independent cell-adhesion activity of claudins, a family of integral membrane proteins localized at tight junctions. Curr Biol 1999; 9: 1035-1038. (Pubitemid 29456172)
74. Van Itallie C, Rahner C, Anderson JM,. Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability. J Clin Invest 2001; 107: 1319-1327. (Pubitemid 32494549)
75. Furuse M, Furuse K, Sasaki H, Tsukita S,. Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. J Cell Biol 2001; 153: 263-272. (Pubitemid 34280213)
76. Amasheh S, Meiri N, Gitter AH, et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci 2002; 115: 4969-4976. (Pubitemid 36061180)
77. Amasheh S, Schmidt T, Mahn M, et al. Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells. Cell Tissue Res 2005; 321: 89-96. (Pubitemid 40984842)
78. Hou J, Gomes AS, Paul DL, Goodenough DA,. Study of claudin function by RNA interference. J Biol Chem 2006; 281: 36117-36123. (Pubitemid 46041345)
79. Daugherty BL, Ward C, Smith T, et al. Regulation of heterotypic claudin compatibility. J Biol Chem 2007; 282: 30005-30013. (Pubitemid 350035274)
80. Furuse M, Sasaki H, Tsukita S,. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 1999; 147: 891-903.
81. Piontek J, Winkler L, Wolburg H, et al. Formation of tight junction: determinants of homophilic interaction between classic claudins. FASEB J 2008; 22: 146-158.
82. Colegio OR, Van Itallie C, Rahner C, Anderson JM,. Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture. Am J Physiol Cell Physiol 2003; 284: C1346-C1354. (Pubitemid 36583375)
83. Furuse M, Hata M, Furuse K, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice. J Cell Biol 2002; 156: 1099-1111. (Pubitemid 34839858)
84. Gow A, Southwood CM, Li JS, et al. CNS myelin and sertoli cell tight junction strands are absent in Osp/claudin-11 null mice. Cell 1999; 99: 649-659. (Pubitemid 30004640)
85. Hadj-Rabia S, Baala L, Vabres P, et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: A tight junction disease. Gastroenterology 2004; 127: 1386-1390. (Pubitemid 39457765)
86. Hampson G, Konrad MA, Scoble J,. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC): compound heterozygous mutation in the claudin 16 (CLDN16) gene. BMC Nephrol 2008; 9: 12.
87. Knohl SJ, Scheinman SJ,. Inherited hypercalciuric syndromes: Dent's disease (CLC-5) and familial hypomagnesemia with hypercalciuria (paracellin-1). Semin Nephrol 2004; 24: 55-60. (Pubitemid 38141845)
88. Miyamoto T, Morita K, Takemoto D, et al. Tight junctions in Schwann cells of peripheral myelinated axons: A lesson from claudin-19-deficient mice. J Cell Biol 2005; 169: 527-538. (Pubitemid 40686702)
89. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 2003; 161: 653-660. (Pubitemid 36578587)
90. Morita K, Sasaki H, Furuse M, Tsukita S,. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 1999; 147: 185-194. (Pubitemid 30211806)
91. Daneman R, Zhou L, Agalliu D, et al. The mouse blood-brain barrier transcriptome: A new resource for understanding the development and function of brain endothelial cells. PLoS One 2010; 5: e13741.
92. Liebner S, Corada M, Bangsow T, et al. Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol 2008; 183: 409-417.
93. Balda MS, Whitney JA, Flores C, et al. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J Cell Biol 1996; 134: 1031-1049. (Pubitemid 26278226)
94. McCarthy KM, Skare IB, Stankewich MC, et al. Occludin is a functional component of the tight junction. J Cell Sci 1996; 109 (pt 9): 2287-2298. (Pubitemid 26325491)
95. Wong V, Gumbiner BM,. A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier. J Cell Biol 1997; 136: 399-409. (Pubitemid 27063089)
96. Saitou M, Furuse M, Sasaki H, et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell 2000; 11: 4131-4142.
97. Raleigh DR, Boe DM, Yu D, et al. Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function. J Cell Biol 2011; 193: 565-582.
98. Laukoetter MG, Nava P, Lee WY, et al. JAM-A regulates permeability and inflammation in the intestine in vivo. J Exp Med 2007; 204: 3067-3076.
99. Martin-Padura I, Lostaglio S, Schneemann M, et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998; 142: 117-127. (Pubitemid 28341144)
100. Palmeri D, van Zante A, Huang CC, et al. Vascular endothelial junction-associated molecule, a novel member of the immunoglobulin superfamily, is localized to intercellular boundaries of endothelial cells. J Biol Chem 2000; 275: 19139-19145. (Pubitemid 30422883)
101. Wallez Y, Huber P,. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta 2008; 1778: 794-809. (Pubitemid 351317803)
102. Williams LA, Martin-Padura I, Dejana E, et al. Identification and characterisation of human junctional adhesion molecule (JAM). Mol Immunol 1999; 36: 1175-1188. (Pubitemid 30078900)
103. Aurrand-Lions M, Johnson-Leger C, Wong C, et al. Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members. Blood 2001; 98: 3699-3707.
104. Cera MR, Del Prete A, Vecchi A, et al. Increased DC trafficking to lymph nodes and contact hypersensitivity in junctional adhesion molecule-A-deficient mice. J Clin Invest 2004; 114: 729-738. (Pubitemid 39578763)
105. Johnson-Leger CA, Aurrand-Lions M, Beltraminelli N, et al. Junctional adhesion molecule-2 (JAM-2) promotes lymphocyte transendothelial migration. Blood 2002; 100: 2479-2486.
106. Ludwig RJ, Zollner TM, Santoso S, et al. Junctional adhesion molecules (JAM)-B and -C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J Invest Dermatol 2005; 125: 969-976.
107. Umeda K, Matsui T, Nakayama M, et al. Establishment and characterization of cultured epithelial cells lacking expression of ZO-1. J Biol Chem 2004; 279: 44785-44794. (Pubitemid 39430889)
108. Lampugnani MG,. Endothelial adherens junctions and the actin cytoskeleton: An 'infinity net'? J Biol 2010; 9: 16.
109. Corada M, Zanetta L, Orsenigo F, et al. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 2002; 100: 905-911. (Pubitemid 34832616)
110. Harris ES, Nelson WJ,. VE-cadherin: At the front, center, and sides of endothelial cell organization and function. Curr Opin Cell Biol 2010; 22: 651-658.
111. Schulte D, Kuppers V, Dartsch N, et al. Stabilizing the VE-cadherin-catenin complex blocks leukocyte extravasation and vascular permeability. EMBO J 2011; 30: 4157-4170.
112. Hirase T, Staddon JM, Saitou M, et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 1997; 110 (pt 14): 1603-1613. (Pubitemid 27338748)
113. Bangsow T, Baumann E, Bangsow C, et al. The epithelial membrane protein 1 is a novel tight junction protein of the blood-brain barrier. J Cereb Blood Flow Metab 2008; 28: 1249-1260. (Pubitemid 351733349)
114. Roux KJ, Amici SA, Notterpek L,. The temporospatial expression of peripheral myelin protein 22 at the developing blood-nerve and blood-brain barriers. J Comp Neurol 2004; 474: 578-588. (Pubitemid 38720426)
115. Ikenouchi J, Furuse M, Furuse K, et al. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J Cell Biol 2005; 171: 939-945. (Pubitemid 41815826)
116. Masuda S, Oda Y, Sasaki H, et al. LSR defines cell corners for tricellular tight junction formation in epithelial cells. J Cell Sci 2011; 124 (pt 4): 548-555.
117. Riazuddin S, Ahmed ZM, Fanning AS, et al. Tricellulin is a tight-junction protein necessary for hearing. Am J Hum Genet 2006; 79: 1040-1051. (Pubitemid 44853475)
118. Beck DW, Vinters HV, Hart MN, Cancilla PA,. Glial cells influence polarity of the blood-brain barrier. J Neuropathol Exp Neurol 1984; 43: 219-224. (Pubitemid 14106299)
119. Betz AL, Firth JA, Goldstein GW,. Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Res 1980; 192: 17-28. (Pubitemid 10102183)
120. Betz AL, Goldstein GW,. Polarity of the blood-brain barrier: neutral amino acid transport into isolated brain capillaries. Science 1978; 202: 225-227. (Pubitemid 9055121)
121. Lippoldt A, Kniesel U, Liebner S, et al. Structural alterations of tight junctions are associated with loss of polarity in stroke-prone spontaneously hypertensive rat blood-brain barrier endothelial cells. Brain Res 2000; 885: 251-261.
122. Wolburg-Buchholz K, Mack AF, Steiner E, et al. Loss of astrocyte polarity marks blood-brain barrier impairment during experimental autoimmune encephalomyelitis. Acta Neuropathol 2009; 118: 219-233.
123. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989; 86: 695-698. (Pubitemid 19037807)
124. Loscher W, Potschka H,. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86-98. (Pubitemid 40128029)
125. Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159-164. (Pubitemid 19039163)
126. Ha SN, Hochman J, Sheridan RP,. Mini review on molecular modeling of P-glycoprotein (Pgp). Curr Top Med Chem 2007; 7: 1525-1529. (Pubitemid 47618065)
127. Sugawara I, Hamada H, Tsuruo T, Mori S,. Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn J Cancer Res 1990; 81: 727-730. (Pubitemid 20246917)
128. Sugawara I,. Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta Pathol Jpn 1990; 40: 545-553. (Pubitemid 20328971)
129. Tanaka Y, Abe Y, Tsugu A, et al. Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas. Virchows Arch 1994; 425: 133-138. (Pubitemid 24312314)
130. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502. (Pubitemid 24153990)
131. Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698-1705.
132. Abbott NJ, Khan EU, Rollinson CM, et al. Drug resistance in epilepsy: The role of the blood-brain barrier. Novartis Found Symp 2002; 243: 38-47; discussion 47-53, 180-185.
133. Potschka H, Fedrowitz M, Loscher W,. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001; 12: 3557-3560. (Pubitemid 33065498)
134. Robey RW, Lazarowski A, Bates SE,. P-glycoprotein-A clinical target in drug-refractory epilepsy? Mol Pharmacol 2008; 73: 1343-1346. (Pubitemid 351574823)
135. Cooray HC, Blackmore CG, Maskell L, Barrand MA,. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002; 13: 2059-2063. (Pubitemid 36005925)
136. Berezowski V, Landry C, Dehouck MP, et al. Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res 2004; 1018: 1-9. (Pubitemid 38942854)
137. Nies AT, Jedlitschky G, Konig J, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004; 129: 349-360. (Pubitemid 39388854)
138. Zhang Y, Han H, Elmquist WF, Miller DW,. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 2000; 876: 148-153.
139. Boado RJ, Li JY, Nagaya M, et al. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci U S A 1999; 96: 12079-12084. (Pubitemid 29502861)
140. Cornford EM, Hyman S, Swartz BE,. The human brain GLUT1 glucose transporter: ultrastructural localization to the blood-brain barrier endothelia. J Cereb Blood Flow Metab 1994; 14: 106-112.
141. Jefferies WA, Brandon MR, Hunt SV, et al. Transferrin receptor on endothelium of brain capillaries. Nature 1984; 312: 162-163. (Pubitemid 14000081)
142. Kido Y, Tamai I, Okamoto M, et al. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm Res 2000; 17: 55-62. (Pubitemid 30121100)
143. Meresse S, Delbart C, Fruchart JC, Cecchelli R,. Low-density lipoprotein receptor on endothelium of brain capillaries. J Neurochem 1989; 53: 340-345. (Pubitemid 19186064)
144. O'Donnell ME, Martinez A, Sun D,. Cerebral microvascular endothelial cell Na-K-Cl cotransport: regulation by astrocyte-conditioned medium. Am J Physiol 1995; 268: C747-C754.
145. De Vivo DC, Leary L, Wang D,. Glucose transporter 1 deficiency syndrome and other glycolytic defects. J Child Neurol 2002; 17 (suppl 3): 3S15-3S23; discussion 3S24-3S25.
146. De Vivo DC, Trifiletti RR, Jacobson RI, et al. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991; 325: 703-709.
147. Withrow CD,. The ketogenic diet: mechanism of anticonvulsant action. Adv Neurol 1980; 27: 635-642.
148. Huang J, Upadhyay UM, Tamargo RJ,. Inflammation in stroke and focal cerebral ischemia. Surg Neurol 2006; 66: 232-245. (Pubitemid 44279808)
149. Henninger DD, Panes J, Eppihimer M, et al. Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol 1997; 158: 1825-1832. (Pubitemid 127469540)
150. Engelhardt B,. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J Neurol Sci 2008; 274: 23-26.
151. Ioannidou S, Deinhardt K, Miotla J, et al. An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis. Proc Natl Acad Sci USA 2006; 103: 16770-16775. (Pubitemid 44737328)
152. Keuschnigg J, Henttinen T, Auvinen K, et al. The prototype endothelial marker PAL-E is a leukocyte trafficking molecule. Blood 2009; 114: 478-484.
153. Shue EH, Carson-Walter EB, Liu Y, et al. Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neurosci 2008; 9: 29.
154. Abbott NJ, Ronnback L, Hansson E,. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53. (Pubitemid 41828930)
155. Igarashi Y, Utsumi H, Chiba H, et al. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. Biochem Biophys Res Commun 1999; 261: 108-112. (Pubitemid 29371626)
156. Lee SW, Kim WJ, Choi YK, et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med 2003; 9: 900-906. (Pubitemid 36889933)
157. Shayan G, Shuler ML, Lee KH,. The effect of astrocytes on the induction of barrier properties in aortic endothelial cells. Biotechnol Prog 2011 Apr 20. doi: 10.1002/btpr.620.
158. Bauer HC, Bauer H, Lametschwandtner A, et al. Neovascularization and the appearance of morphological characteristics of the blood-brain barrier in the embryonic mouse central nervous system. Brain Res Dev Brain Res 1993; 75: 269-278. (Pubitemid 23293577)
159. Bauer HC, Steiner M, Bauer H,. Embryonic development of the CNS microvasculature in the mouse: new insights into the structural mechanisms of early angiogenesis. EXS 1992; 61: 64-68.
160. Ek CJ, Dziegielewska KM, Stolp H, Saunders NR,. Functional effectiveness of the blood-brain barrier to small water-soluble molecules in developing and adult opossum (Monodelphis domestica). J Comp Neurol 2006; 496: 13-26.
161. Daneman R, Agalliu D, Zhou L, et al. Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc Natl Acad Sci U S A 2009; 106: 641-646.
162. Stenman JM, Rajagopal J, Carroll TJ, et al. Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science 2008; 322: 1247-1250.
163. Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68: 409-427.
164. Dohgu S, Takata F, Yamauchi A, et al. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res 2005; 1038: 208-215. (Pubitemid 40332685)
165. Hori S, Ohtsuki S, Hosoya K, et al. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem 2004; 89: 503-513. (Pubitemid 38495998)
166. Macdonald JA, Murugesan N, Pachter JS,. Endothelial cell heterogeneity of blood-brain barrier gene expression along the cerebral microvasculature. J Neurosci Res 2010; 88: 1457-1474.
167. Broadwell RD, Brightman MW,. Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood. J Comp Neurol 1976; 166: 257-283.
168. Gross PM,. Circumventricular organ capillaries. Prog Brain Res 1992; 91: 219-233.
169. Wolburg H, Paulus W,. Choroid plexus: biology and pathology. Acta Neuropathol 2010; 119: 75-88.
170. Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M,. The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol 2011; 70: 194-206.
171. Sharma HS,. Pathophysiology of blood-spinal cord barrier in traumatic injury and repair. Curr Pharm Des 2005; 11: 1353-1389. (Pubitemid 40598002)
172. Shepro D, Morel NM,. Pericyte physiology. FASEB J 1993; 7: 1031-1038. (Pubitemid 23243445)
173. Frank RN, Dutta S, Mancini MA,. Pericyte coverage is greater in the retinal than in the cerebral capillaries of the rat. Invest Ophthalmol Vis Sci 1987; 28: 1086-1091. (Pubitemid 17089946)
174. Frank RN, Turczyn TJ, Das A,. Pericyte coverage of retinal and cerebral capillaries. Invest Ophthalmol Vis Sci 1990; 31: 999-1007. (Pubitemid 20197621)
175. Stolp HB, Dziegielewska KM, Ek CJ, et al. Breakdown of the blood-brain barrier to proteins in white matter of the developing brain following systemic inflammation. Cell Tissue Res 2005; 320: 369-378. (Pubitemid 40884138)
176. Anderson KD, Pan L, Yang XM, et al. Angiogenic sprouting into neural tissue requires Gpr124, an orphan G protein-coupled receptor. Proc Natl Acad Sci U S A 2011; 108: 2807-2812.
177. Cullen M, Elzarrad MK, Seaman S, et al. GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier. Proc Natl Acad Sci U S A 2011; 108: 5759-5764.
178. Kuhnert F, Mancuso MR, Shamloo A, et al. Essential regulation of CNS angiogenesis by the orphan G protein-coupled receptor GPR124. Science 2010; 330: 985-989.
179. Nag S, Manias JL, Stewart DJ,. Pathology and new players in the pathogenesis of brain edema. Acta Neuropathol 2009; 118: 197-217.
180. Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV,. Inflammation and brain edema: new insights into the role of chemokines and their receptors. Acta Neurochir Suppl 2006; 96: 444-450.
181. Unterberg AW, Stover J, Kress B, Kiening KL,. Edema and brain trauma. Neuroscience 2004; 129: 1021-1029. (Pubitemid 39556253)
182. Correale J, Villa A,. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting. Autoimmunity 2007; 40: 148-160.
183. Oby E, Janigro D,. The blood-brain barrier and epilepsy. Epilepsia 2006; 47: 1761-1774. (Pubitemid 44730046)
184. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990; 113 (pt 5): 1477-1489. (Pubitemid 20385925)
185. Belayev L, Busto R, Zhao W, Ginsberg MD,. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 1996; 739: 88-96. (Pubitemid 26387366)
186. Huang ZG, Xue D, Preston E, et al. Biphasic opening of the blood-brain barrier following transient focal ischemia: effects of hypothermia. Can J Neurol Sci 1999; 26: 298-304. (Pubitemid 29522816)
187. Jiao H, Wang Z, Liu Y, et al. Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the blood-brain barrier in a focal cerebral ischemic insult. J Mol Neurosci 2011; 44: 130-139.
188. Kuroiwa T, Ting P, Martinez H, Klatzo I,. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol 1985; 68: 122-129. (Pubitemid 16242137)
189. Lassmann H,. Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol 2005; 15: 217-222. (Pubitemid 41161177)
190. Lassmann H, Bruck W, Lucchinetti C,. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121. (Pubitemid 32201673)
191. Bielekova B, Kadom N, Fisher E, et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005; 65: 1071-1076. (Pubitemid 41429633)
192. Cotton F, Weiner HL, Jolesz FA, Guttmann CR,. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003; 60: 640-646. (Pubitemid 36246083)
193. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29: 548-555.
194. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661-669. (Pubitemid 23333237)
195. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996; 46: 373-378. (Pubitemid 26081316)
196. Zivadinov R, Cox JL,. Neuroimaging in multiple sclerosis. Int Rev Neurobiol 2007; 79: 449-474.
197. Bradl M, Lassmann H,. Progressive multiple sclerosis. Semin Immunopathol 2009; 31: 455-465.
198. Padden M, Leech S, Craig B, et al. Differences in expression of junctional adhesion molecule-A and beta-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology. Acta Neuropathol 2007; 113: 177-186. (Pubitemid 46158150)
199. Kirk J, Plumb J, Mirakhur M, McQuaid S,. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003; 201: 319-327. (Pubitemid 37258943)
200. Leech S, Kirk J, Plumb J, McQuaid S,. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007; 33: 86-98. (Pubitemid 46090313)
201. Plumb J, McQuaid S, Mirakhur M, Kirk J,. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002; 12: 154-169. (Pubitemid 34259917)
202. Mihaly A, Bozoky B,. Immunohistochemical localization of extravasated serum albumin in the hippocampus of human subjects with partial and generalized epilepsies and epileptiform convulsions. Acta Neuropathol 1984; 65: 25-34. (Pubitemid 15191144)
203. van Vliet EA, da Costa Araujo S, Redeker S, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007; 130: 521-534. (Pubitemid 46181105)
204. Neuwelt EA, Specht HD, Howieson J, et al. Osmotic blood-brain barrier modification: clinical documentation by enhanced CT scanning and/or radionuclide brain scanning. AJR Am J Roentgenol 1983; 141: 829-835. (Pubitemid 13006715)
205. Roman-Goldstein S, Clunie DA, Stevens J, et al. Osmotic blood-brain barrier disruption: CT and radionuclide imaging. AJNR Am J Neuroradiol 1994; 15: 581-590. (Pubitemid 24089556)
206. Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003; 118: 417-429. (Pubitemid 36423257)
207. Marchi N, Hallene KL, Kight KM, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2004; 2: 37.
208. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995; 36: 1-6.
209. Zlokovic BV,. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202-208. (Pubitemid 40445527)
210. Ryu JK, McLarnon JG,. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med 2009; 13: 2911-2925.
211. Pluta R,. Is the ischemic blood-brain barrier insufficiency responsible for full-blown Alzheimer's disease? Neurol Res 2006; 28: 665-671. (Pubitemid 44433327)
212. Apostolski S, Nikolic J, Bugarski-Prokopljevic C, et al. Serum and CSF immunological findings in ALS. Acta Neurol Scand 1991; 83: 96-98.
213. Meucci G, Rossi G, Bettini R, et al. Laser nephelometric evaluation of albumin, IgG and alpha 2-macroglobulin: Applications to the study of alterations of the blood-brain barrier. J Neurol Sci 1993; 118: 73-78. (Pubitemid 23269969)
214. Engelhardt JI, Tajti J, Appel SH,. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 1993; 50: 30-36. (Pubitemid 23019197)
215. Garbuzova-Davis S, Haller E, Saporta S, et al. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res 2007; 1157: 126-137. (Pubitemid 46935078)
216. Garbuzova-Davis S, Saporta S, Haller E, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One 2007; 2: e1205.
217. Nicaise C, Mitrecic D, Demetter P, et al. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res 2009; 1301: 152-162.
218. Zhong Z, Deane R, Ali Z, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 2008; 11: 420-422. (Pubitemid 351441888)
219. Drozdzik M, Bialecka M, Mysliwiec K, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: A possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003; 13: 259-263. (Pubitemid 36583992)
220. Bartels AL, van Berckel BN, Lubberink M, et al. Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 505-508.
221. Bartels AL, Willemsen AT, Kortekaas R, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm 2008; 115: 1001-1009.
222. Desai Bradaric B, Patel A, Schneider JA, et al. Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm 2012; 119: 59-71.
223. Clark AW, Krekoski CA, Bou SS, et al. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997; 238: 53-56. (Pubitemid 28015782)
224. Heo JH, Lucero J, Abumiya T, et al. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-633. (Pubitemid 30161214)
225. Montaner J, Alvarez-Sabin J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke: Temporal profile and relation to neurological impairment. Stroke 2001; 32: 1759-1766. (Pubitemid 32772204)
226. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006; 37: 1399-1406. (Pubitemid 44305716)
227. Rosenberg GA, Navratil M, Barone F, Feuerstein G,. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996; 16: 360-366. (Pubitemid 26125324)
228. Asahi M, Asahi K, Jung JC, et al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000; 20: 1681-1689.
229. Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 29: 1020-1030. (Pubitemid 28228167)
230. Bauer AT, Burgers HF, Rabie T, Marti HH,. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cereb Blood Flow Metab 2010; 30: 837-848.
231. Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007; 27: 697-709. (Pubitemid 46474608)
232. Gidday JM, Gasche YG, Copin JC, et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005; 289: H558-H568. (Pubitemid 41129369)
233. Justicia C, Panes J, Sole S, et al. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 2003; 23: 1430-1440. (Pubitemid 38018261)
234. Jin R, Yang G, Li G,. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010; 38: 376-385.
235. Bates DO, Curry FE,. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol 1997; 273: H687-H694.
236. Hayashi T, Abe K, Suzuki H, Itoyama Y,. Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 1997; 28: 2039-2044. (Pubitemid 27459016)
237. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106: 829-838.
238. Su JJ, Osoegawa M, Matsuoka T, et al. Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 2006; 243: 21-30.
239. Argaw AT, Gurfein BT, Zhang Y, et al. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A 2009; 106: 1977-1982.
240. Koyama J, Miyake S, Sasayama T, et al. The novel VEGF receptor antagonist, VGA1155, reduces edema, decreases infarct and improves neurological function after stroke in rats. Kobe J Med Sci 2010; 56: E1-E11.
241. van Bruggen N, Thibodeaux H, Palmer JT, et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 1999; 104: 1613-1620. (Pubitemid 30002373)
242. Pun PB, Lu J, Moochhala S,. Involvement of ROS in BBB dysfunction. Free Radic Res 2009; 43: 348-364.
243. Olesen SP,. Free oxygen radicals decrease electrical resistance of microvascular endothelium in brain. Acta Physiol Scand 1987; 129: 181-187.
244. Agarwal R, Shukla GS,. Potential role of cerebral glutathione in the maintenance of blood-brain barrier integrity in rat. Neurochem Res 1999; 24: 1507-1514.
245. Maier CM, Hsieh L, Crandall T, et al. Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann Neurol 2006; 59: 929-938. (Pubitemid 43830925)
246. Schreibelt G, Kooij G, Reijerkerk A, et al. Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J 2007; 21: 3666-3676. (Pubitemid 350075154)
247. Prat A, Biernacki K, Pouly S, et al. Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol 2000; 59: 896-906.
248. Relton JK, Beckey VE, Hanson WL, Whalley ET,. CP-0597, a selective bradykinin B2 receptor antagonist, inhibits brain injury in a rat model of reversible middle cerebral artery occlusion. Stroke 1997; 28: 1430-1436. (Pubitemid 27300683)
249. Gobel K, Pankratz S, Schneider-Hohendorf T, et al. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun 2011; 36: 106-114.
250. Sharief MK, Noori MA, Ciardi M, et al. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol 1993; 43: 15-21. (Pubitemid 23103635)
251. Sharief MK, Thompson EJ,. In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 1992; 38: 27-33.
252. Tsukada N, Miyagi K, Matsuda M, et al. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 1991; 104: 230-234.
253. Liu T, Clark RK, McDonnell PC, et al. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 1994; 25: 1481-1488. (Pubitemid 24198599)
254. Kim KS, Wass CA, Cross AS, Opal SM,. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res 1992; 11: 293-298. (Pubitemid 23014635)
255. Wright JL, Merchant RE,. Blood-brain barrier changes following intracerebral injection of human recombinant tumor necrosis factor-alpha in the rat. J Neurooncol 1994; 20: 17-25. (Pubitemid 24299471)
256. Ozaki H, Ishii K, Horiuchi H, et al. Cutting edge: combined treatment of TNF-alpha and IFN-gamma causes redistribution of junctional adhesion molecule in human endothelial cells. J Immunol 1999; 163: 553-557. (Pubitemid 29328054)
257. Wojciak-Stothard B, Entwistle A, Garg R, Ridley AJ,. Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol 1998; 176: 150-165. (Pubitemid 28277205)
258. Relton JK, Rothwell NJ,. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992; 29: 243-246.
259. Rothwell NJ, Relton JK,. Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage. Cerebrovasc Brain Metab Rev 1993; 5: 178-198.
260. Sozen T, Tsuchiyama R, Hasegawa Y, et al. Role of interleukin-1beta in early brain injury after subarachnoid hemorrhage in mice. Stroke 2009; 40: 2519-2525.
261. Relton JK, Martin D, Thompson RC, Russell DA,. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996; 138: 206-213. (Pubitemid 26135199)
262. McColl BW, Rothwell NJ, Allan SM,. Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci 2008; 28: 9451-9462.
263. Calabresi PA, Prat A, Biernacki K, et al. T lymphocytes conditioned with interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J Neuroimmunol 2001; 115: 161-167. (Pubitemid 32245664)
264. Kis B, Abraham CS, Deli MA, et al. Adrenomedullin, an autocrine mediator of blood-brain barrier function. Hypertens Res 2003; 26 (suppl): S61-S70. (Pubitemid 36372318)
265. Kraus J, Ling AK, Hamm S, et al. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 2004; 56: 192-205. (Pubitemid 39037915)
266. Kraus J, Voigt K, Schuller AM, et al. Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro. Mult Scler 2008; 14: 843-852.
267. Sonobe Y, Takeuchi H, Kataoka K, et al. Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cepsilon-dependent manner. J Biol Chem 2009; 284: 31834-31842.
268. Bartholomaus I, Kawakami N, Odoardi F, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009; 462: 94-98.
269. Kivisakk P, Imitola J, Rasmussen S, et al. Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol 2009; 65: 457-469.
270. Love S, Barber R,. Expression of P-selectin and intercellular adhesion molecule-1 in human brain after focal infarction or cardiac arrest. Neuropathol Appl Neurobiol 2001; 27: 465-473. (Pubitemid 34264262)
271. Okada Y, Copeland BR, Mori E, et al. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994; 25: 202-211.
272. Bowes MP, Zivin JA, Rothlein R,. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol 1993; 119: 215-219. (Pubitemid 23132018)
273. Connolly ES Jr, Winfree CJ, Springer TA, et al. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996; 97: 209-216. (Pubitemid 26021710)
274. Mayadas TN, Johnson RC, Rayburn H, et al. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74: 541-554. (Pubitemid 23244619)
275. Doring A, Wild M, Vestweber D, et al. E- and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL/6 and SJL mice. J Immunol 2007; 179: 8470-8479.
276. Baron JL, Madri JA, Ruddle NH, et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993; 177: 57-68. (Pubitemid 23008085)
277. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
278. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66.
279. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381. (Pubitemid 41132342)
280. Richardson-Burns SM, Kleinschmidt-DeMasters BK, DeBiasi RL, Tyler KL,. Progressive multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central nervous system of patients with and without AIDS. Arch Neurol 2002; 59: 1930-1936. (Pubitemid 35424652)
281. Cayrol R, Wosik K, Berard JL, et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 2008; 9: 137-145.
282. Ifergan I, Kebir H, Terouz S, et al. Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions. Ann Neurol 2011; 70: 751-763.
283. Arima Y, Harada M, Kamimura D, et al. Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell 2012; 148: 447-457.
284. Engelhardt B, Wolburg H,. Mini-review: Transendothelial migration of leukocytes: Through the front door or around the side of the house? Eur J Immunol 2004; 34: 2955-2963. (Pubitemid 39549374)
285. Nag S, Venugopalan R, Stewart DJ,. Increased caveolin-1 expression precedes decreased expression of occludin and claudin-5 during blood-brain barrier breakdown. Acta Neuropathol 2007; 114: 459-469. (Pubitemid 47521502)
286. Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007; 204: 571-582. (Pubitemid 46457080)
287. Akassoglou K, Adams RA, Bauer J, et al. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci USA 2004; 101: 6698-6703. (Pubitemid 38586037)
288. Paul J, Strickland S, Melchor JP,. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 2007; 204: 1999-2008. (Pubitemid 47236333)
289. Gasque P, Dean YD, McGreal EP, et al. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000; 49: 171-186. (Pubitemid 30445228)
290. Veerhuis R, Nielsen HM, Tenner AJ,. Complement in the brain. Mol Immunol 2011; 48: 1592-1603.
291. Hossain S, Akaike T, Chowdhury EH,. Current approaches for drug delivery to central nervous system. Curr Drug Deliv 2010; 7: 389-397.
292. Soni V, Jain A, Khare P, et al. Potential approaches for drug delivery to the brain: past, present, and future. Crit Rev Ther Drug Carrier Syst 2010; 27: 187-236.
293. Haluska M, Anthony ML,. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors. Clin J Oncol Nurs 2004; 8: 263-267.
294. Marchi N, Angelov L, Masaryk T, et al. Seizure-promoting effect of blood-brain barrier disruption. Epilepsia 2007; 48: 732-742. (Pubitemid 46587627)
295. Siegal T, Rubinstein R, Bokstein F, et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg 2000; 92: 599-605. (Pubitemid 30180664)
296. Kageyama T, Nakamura M, Matsuo A, et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res 2000; 879: 115-121.
297. Shi N, Boado RJ, Pardridge WM,. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm Res 2001; 18: 1091-1095. (Pubitemid 32900392)
298. Zhang Y, Pardridge WM,. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res 2001; 889: 49-56. (Pubitemid 32146264)
299. Boado RJ, Zhang Y, Pardridge WM,. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 2007; 96: 381-391. (Pubitemid 46232272)
300. Roger M, Clavreul A, Venier-Julienne MC, et al. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 2011; 32: 2106-2116.
301. Yang H,. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res 2010; 27: 1759-1771.
302. Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3: 84ra44.
303. Shen L, Weber CR, Turner JR,. The tight junction protein complex undergoes rapid and continuous molecular remodeling at steady state. J Cell Biol 2008; 181: 683-695. (Pubitemid 351717514)
304. Deane R, Bell RD, Sagare A, Zlokovic BV,. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009; 8: 16-30.
305. Deane R, Sagare A, Hamm K, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008; 118: 4002-4013.
306. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489-1499. (Pubitemid 32038587)
307. Vorbrodt AW, Dobrogowska DH,. Molecular anatomy of interendothelial junctions in human blood-brain barrier microvessels. Folia Histochem Cytobiol 2004; 42: 67-75. (Pubitemid 38714693)
308. Yeung D, Manias JL, Stewart DJ, Nag S,. Decreased junctional adhesion molecule-A expression during blood-brain barrier breakdown. Acta Neuropathol 2008; 115: 635-642.
309. Lauritzen F, de Lanerolle NC, Lee TS, et al. Monocarboxylate transporter 1 is deficient on microvessels in the human epileptogenic hippocampus. Neurobiol Dis 2011; 41: 577-584.
310. Pellerin L, Pellegri G, Martin JL, Magistretti PJ,. Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain. Proc Natl Acad Sci U S A 1998; 95: 3990-3995. (Pubitemid 28173241)
311. Roberts LM, Black DS, Raman C, et al. Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience 2008; 155: 423-438.
312. Lyck R, Ruderisch N, Moll AG, et al. Culture-induced changes in blood-brain barrier transcriptome: implications for amino-acid transporters in vivo. J Cereb Blood Flow Metab 2009; 29: 1491-1502.
313. Boado RJ, Li JY, Pardridge WM,. Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein. Pediatr Res 2004; 55: 557-560. (Pubitemid 38405839)
314. O'Kane RL, Martinez-Lopez I, DeJoseph MR, et al. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 1999; 274: 31891-31895.
315. Shawahna R, Uchida Y, Decleves X, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011; 8: 1332-1341.
316. Ruderisch N, Virgintino D, Makrides V, Verrey F,. Differential axial localization along the mouse brain vascular tree of luminal sodium-dependent glutamine transporters Snat1 and Snat3. J Cereb Blood Flow Metab 2011; 31: 1637-1647.
317. Lam TI, Wise PM, O'Donnell ME,. Cerebral microvascular endothelial cell Na/H exchange: evidence for the presence of NHE1 and NHE2 isoforms and regulation by arginine vasopressin. Am J Physiol Cell Physiol 2009; 297: C278-C289.
318. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-913. (Pubitemid 36889934)
319. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006; 112: 405-415. (Pubitemid 44469161)
320. Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004; 43: 333-344. (Pubitemid 39061126)
321. Ronaldson PT, Finch JD, Demarco KM, et al. Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier. J Pharmacol Exp Ther 2011; 336: 827-839.
322. Gao B, Hagenbuch B, Kullak-Ublick GA, et al. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 2000; 294: 73-79. (Pubitemid 30434672)
323. Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 2005; 65: 11419-11428. (Pubitemid 41821699)
324. Ohtsuki S, Asaba H, Takanaga H, et al. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 2002; 83: 57-66.
325. Gu Y, Zheng G, Xu M, et al. Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and reperfusion injury. J Neurochem 2012; 120: 147-156.
326. Liu LB, Xue YX, Liu YH,. Bradykinin increases the permeability of the blood-tumor barrier by the caveolae-mediated transcellular pathway. J Neurooncol 2010; 99: 187-194.
327. Zhao LN, Yang ZH, Liu YH, et al. Vascular endothelial growth factor increases permeability of the blood-tumor barrier via caveolae-mediated transcellular pathway. J Mol Neurosci 2011; 44: 122-129.
328. Huang J, Choudhri TF, Winfree CJ, et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke 2000; 31: 3047-3053.
329. Jin AY, Tuor UI, Rushforth D, et al. Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic stroke: A future therapeutic target for treatment of stroke. BMC Neurosci 2010; 11: 12.
330. Lyck R, Reiss Y, Gerwin N, et al. T-cell interaction with ICAM-1/ICAM-2 double-deficient brain endothelium in vitro: The cytoplasmic tail of endothelial ICAM-1 is necessary for transendothelial migration of T cells. Blood 2003; 102: 3675-3683. (Pubitemid 37409388)
331. Agarwal N, Lippmann ES, Shusta EV,. Identification and expression profiling of blood-brain barrier membrane proteins. J Neurochem 2010; 112: 625-635.
332. Ghandour MS, Langley OK, Zhu XL, et al. Carbonic anhydrase IV on brain capillary endothelial cells: A marker associated with the blood-brain barrier. Proc Natl Acad Sci U S A 1992; 89: 6823-6827.
333. Igakura T, Kadomatsu K, Taguchi O, et al. Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating odor, lymphocyte response, and blood-brain barrier. Biochem Biophys Res Commun 1996; 224: 33-36. (Pubitemid 26252407)
334. Sameshima T, Nabeshima K, Toole BP, et al. Correlation of emmprin expression in vascular endothelial cells with blood-brain-barrier function: A study using magnetic resonance imaging enhanced by Gd-DTPA and immunohistochemistry in brain tumors. Virchows Arch 2003; 442: 577-584. (Pubitemid 36819252)
335. Kondo T, Hafezi-Moghadam A, Thomas K, et al. Mice lacking insulin or insulin-like growth factor 1 receptors in vascular endothelial cells maintain normal blood-brain barrier. Biochem Biophys Res Commun 2004; 317: 315-320. (Pubitemid 38452484)
336. Pardridge WM, Eisenberg J, Yang J,. Human blood-brain barrier insulin receptor. J Neurochem 1985; 44: 1771-1778. (Pubitemid 15000282)
337. Orlowski M, Sessa G, Green JP,. Gamma-glutamyl transpeptidase in brain capillaries: possible site of a blood-brain barrier for amino acids. Science 1974; 184: 66-68.
338. Moustafa RR, Baron JC,. Clinical review: Imaging in ischaemic stroke-implications for acute management. Crit Care 2007; 11: 227.
339. Rother J,. CT and MRI in the diagnosis of acute stroke and their role in thrombolysis. Thromb Res 2001; 103 (suppl 1): S125-S133.
340. Akopov SE, Simonian NA, Grigorian GS,. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996; 27: 1739-1743. (Pubitemid 26332496)
341. Kochanek PM, Hallenbeck JM,. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23: 1367-1379.